BONEX logo

Bonesupport Holding AB (publ) Stock Price

OM:BONEX Community·SEK 17.6b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 44 Fair Values set on narratives written by author

BONEX Share Price Performance

SEK 263.60
-47.60 (-15.30%)
SEK 366.60
Fair Value
SEK 263.60
-47.60 (-15.30%)
28.1% undervalued intrinsic discount
SEK 366.60
Fair Value
Price SEK 263.60
AnalystConsensusTarget SEK 366.60
AnalystLowTarget SEK 310.00
AnalystHighTarget SEK 428.00

BONEX Community Narratives

AnalystConsensusTarget·
Fair Value SEK 366.6 28.1% undervalued intrinsic discount

Positive Clinical Results And US Launch Will Drive Future Success

0users have liked this narrative
0users have commented on this narrative
26users have followed this narrative
AnalystLowTarget·
Fair Value SEK 310 15.0% undervalued intrinsic discount

Slow Trauma Center Adoption And Regulatory Hurdles Will Eventually Support A Healthier Business Mix

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystHighTarget·
Fair Value SEK 428 38.4% undervalued intrinsic discount

US Trauma Expansion And New Surgical Uses Will Transform This Bone Regeneration Specialist

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
SEK 366.6
28.1% undervalued intrinsic discount
Revenue
31.12% p.a.
Profit Margin
31.54%
Future PE
35.37x
Price in 2029
SEK 424.75
SEK 310
15.0% undervalued intrinsic discount
Revenue
27.56% p.a.
Profit Margin
28.79%
Future PE
35.87x
Price in 2029
SEK 361.9
SEK 428
38.4% undervalued intrinsic discount
Revenue
35.55% p.a.
Profit Margin
28.48%
Future PE
41.48x
Price in 2029
SEK 499.81

Trending Discussion

Updated Narratives

BONEX logo

BONEX: Clinical Pilot Outcomes And 2026 Sales Outlook Will Support Future Upside Potential

Fair Value: SEK 366.6 28.1% undervalued intrinsic discount
26 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
BONEX logo

Slow Trauma Center Adoption And Regulatory Hurdles Will Eventually Support A Healthier Business Mix

Fair Value: SEK 310 15.0% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
BONEX logo

US Trauma Expansion And New Surgical Uses Will Transform This Bone Regeneration Specialist

Fair Value: SEK 428 38.4% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Exceptional growth potential with flawless balance sheet.

0 Risks
4 Rewards

Bonesupport Holding AB (publ) Key Details

SEK 1.2b

Revenue

SEK 87.3m

Cost of Revenue

SEK 1.1b

Gross Profit

SEK 945.2m

Other Expenses

SEK 142.2m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Apr 22, 2026
2.13
92.57%
12.10%
0%
View Full Analysis

About BONEX

Founded
1999
Employees
143
CEO
Torbjorn Skold
WebsiteView website
www.bonesupport.com

Bonesupport Holding AB (publ), an orthobiologics company, develops and sells injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; CERAMENT V, an injectable ceramic bone graft substitute that remodels to host bone and elutes Vancomycin during the critical first 30 days of bone healing, as well as treats and prevents bone infection. It also offers CERAMENT Bead Tray, an adjunctive local delivery option for surgeons for targeted delivery to osseous defects and for dead space management. In addition, the company develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, and foot and ankle surgery. Bonesupport Holding AB (publ) was founded in 1999 and is headquartered in Lund, Sweden.

Recent BONEX News & Updates

Recent updates

No updates